Trametinib and Everolimus for the Treatment of Pediatric and Young Adult Patients With Recurrent Low Grade Gliomas (PNOC021)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Recurrent Low Grade Glioma
  • Age: Between 1 years - 25 years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Participants must have histologically confirmed diagnosis of a LGG (WHO grade I-II) that is recurrent or progressive after prior treatment (biologic, chemotherapy or radiation therapy). 2) For enrollment, snap frozen tissue (150 mg) or 10 unstained 10 um FFPE slides for comprehensive genomic testing or results of prior testing is required. 3) Participants must have evaluable disease. 4) Participants must have received prior therapy other than surgery and must have fully recovered from the acute toxic effects of all prior chemotherapy, biologics, immunotherapy, or radiotherapy prior to entering this study.

You may not be eligible for this study if the following are true:

  • 1) History of allergic reactions attributed to compounds of similar chemical or biologic composition to everolimus or trametinib. 2) Participants without available tissue from prior surgery. 3) Participants who are receiving any other investigational agent for treatment of their tumor.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.